Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04331730 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Alkahest.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT04331730 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Alkahest. The registered enrollment target is 107 participants, below the 405-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT04331730, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aflibercept
- DRUG AKST4290
Study Locations (20)
Other
- Internationale Innovative Ophthalmochirurgie GbR - Düsseldorf
- nordBLICK Augenklinik Bellevue - Kiel
- Augentagesklinik Rheine - Rheine
- Jahn Ferenc Dél-pesti Kórház (Jahn Ferenc South-Pest Hospital) - Budapest
- Magyar Honvédség Egészségügyi Központ, Szemészeti Osztály (Medical Centre, Hungarian Defence Forces, Ophthalmology Department) - Budapest
- Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház (Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital) - Miskolc
- GANGLION Orvosi Központ - Pécs
- Szegedi Tudományegyetem Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Szemészeti Klinika, (University of Szeged Faculty of Medicine, Albert-Szent Gyorgyi Health Care, Department of Ophthalmology) - Szekszárd
- Tęczówka (IRIS) - Bialystok
- Specjalistyczny Ośrodek Okulistyczny Oculomedica (Specialized Eye Center Oculomedica) - Bydgoszcz
- PROVISUS Sp. z o.o. - Częstochowa
- Optimum Profesorskie Centrum Okulistyki - Gdansk
- Centrum Medyczne Dietla 19 Sp zoo - Krakow
- Klinika Chirurgii Siatkówki i Ciała Szklistego Medical University in Lublin - Lublin
- Szpital św. Wojciecha - Poznan
- ArtOptica Salon Okulistyczno - Suwałki
- Centrum Medyczne UNO-MED - Tarnów
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
Florida
- Retina Vitreous Associates of FL - St. Petersburg
Nevada
- Sierra Eye Associates - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04331730
The ClinicalTrials.gov registry entry for NCT04331730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 405-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (74% lower). The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04331730 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04331730 about?
NCT04331730 is a clinical study titled "A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD". This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
What is the current status of trial NCT04331730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2020-01-28. Estimated completion is 2021-09-16.
What conditions does trial NCT04331730 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT04331730?
The interventions under investigation include: Placebo (DRUG), Aflibercept (DRUG), AKST4290 (DRUG).
Who is sponsoring clinical trial NCT04331730?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04331730 being conducted?
This trial has 20 study locations across California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
COMPLETED · Phase 2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
COMPLETED · Phase 2
-
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.